Introduction:
Syngene Biologics plans to invest US$98 million to open newly upgraded biologics facility in Bangalore, India.
Features:
The new facility with two production suites, each housing with 2KL single-use bioreactors, boasts a total capacity of 20KL for drug substance production.
Additionally, it features two high-speed vial filling lines capable of producing up to 1 million vials per day, accommodating fill volumes ranging from 1 to 100mL. Complementing the production capacity, there's a development suite dedicated to clinical drug substance supply, equipped with a 500L single-use bioreactor.
This US$98 million investment significantly enhances the manufacturing capabilities, tripling bio manufacturing capacity and complementing the existing commercial manufacturing site.
The facility is strategically located alongside around 170 R&D scientists, ensuring seamless integration from discovery biology services to clinical and commercial manufacturing.
Future expansion plans include the addition of two vial filling isolator lines, with capacities of 600 vials/minute and 100 vials/minute respectively, as well as expansion into perfusion cell culture processing for drug substance manufacturing.
The site's integration with nearby R&D, drug substance, and drug product capabilities not only accelerates time to clinical trials but also optimises cost efficiencies throughout the production process.
The upgraded biologics facility, known as Unit 3, is scheduled to begin its clinical and commercial supply operations in the second half of 2024.
Specifications:
Name Syngene Biologics
Type New Construction
Budget US$98 million
Year 2024
